A dangerous new strain of ketamine, dubbed 'Rhino Ket,' is circulating and posing a severe threat, particularly due to its use by predators to incapacitate victims. This potent drug, often mixed with medetomidine—a powerful veterinary tranquilizer—can lead to extreme sedation, paralysis, and increased vulnerability, making users susceptible to sexual assault and overdose. The trend is impacting a wide demographic, including young professionals and teenagers, who may be unaware of the drug's enhanced risks.
One victim, a 28-year-old nurse practitioner identified as Becky, described a terrifying experience after taking a batch of ketamine that had been cut with medetomidine. She found herself fully conscious but completely paralyzed, a state during which her dealer sexually assaulted her. Her dealer admitted to regularly selling this mixture to incapacitate young women for assault. Becky, fearing job loss and unable to report the crime, suffered a severe breakdown, grappling with PTSD and guilt.
Another victim, 20-year-old trainee accountant Mark, shared how the drug led him to crash his car while driving. He described the drug hitting him like a "sledgehammer," causing his brain to shut down and leading to his collapse at the wheel. His friends, fearing career repercussions, removed him from the vehicle before emergency services arrived. Mark, who believed he was streetwise, narrowly avoided a fatal overdose.
These incidents highlight a disturbing trend where ketamine is being adulterated with medetomidine, a sedative up to 200 times more potent than xylazine, another common cutting agent. This combination can cause prolonged sedation, breathing difficulties, and a significantly higher risk of overdose and death. Drug testing facilities and local authorities, including Manchester University and Wirral Ways, have issued stark warnings about the presence of medetomidine in ketamine samples circulating in areas like Manchester and Merseyside.
Psychotherapist and addictions counsellor Steve Pope, who is treating numerous victims of 'Rhino Ket,' notes the drug's rapid spread. His caseload in one part of Lancashire has surpassed 60 confirmed cases, with cases involving teenagers being particularly concerning. One 15-year-old student, Emma, experienced a virtual coma and has no memory of an assault after sharing a small amount of what she believed was ketamine with friends. Another, 16-year-old Anna, suffered memory loss leading to an unprovoked street attack and later threw herself from a second-floor window after a contaminated batch. Even a 14-year-old, Ryan, was found wandering on the M55 motorway after taking what he thought was regular ketamine.
The drug's reach extends into professional circles, with Pope reporting cases among accountants, trainee lawyers, semi-professional footballers, members of the armed forces, and medical students. He emphasizes that these individuals, despite their understanding or perceived control, are equally vulnerable to the drug's potent effects.
Medetomidine's presence in the ketamine supply is believed to be an effort to increase bulk and enhance sedative effects. Crucially, its effects cannot be reversed by naloxone, the standard antidote for opioid overdoses, leaving users in a potentially irreversible state if too much is taken. While the UK government has moved to classify medetomidine as a Class C drug, experts argue this classification may not be sufficient to deter organized crime groups involved in its distribution. Drug awareness services recommend testing ketamine for medetomidine, but the cost of testing kits is a barrier for many users purchasing cheaper, adulterated batches.